Feb 26, 2026
How Does Ibogaine Work in the Brain? The Neuroscience Behind Addiction Interruption
When people hear that ibogaine can eliminate opioid withdrawal in 24 hours and reduce cravings for months—all from a sin...
Read Article →900+
Patients Treated
Clinical data available
M.D.
Clinical Director
Board certified addiction medicine
24/7
Cardiac Monitoring
Continuous telemetry
90 Days
Aftercare Program
Post-treatment integration
DA
Medically reviewed by Dr Arellano, M.D.
Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 900 patients treated.
Last reviewed: March 2026
Clinical Overview
Ibogaine: Pharmacological Summary for Clinicians
Ibogaine (12-methoxyibogamine) is an indole alkaloid derived from Tabernanthe iboga root bark. It acts as a multi-target ligand with clinically relevant affinity for: mu-opioid receptors (partial agonist/antagonist), kappa-opioid receptors (agonist), NMDA receptors (non-competitive antagonist), serotonin transporter (inhibitor), dopamine transporter (inhibitor), sigma-2 receptors (agonist), and nicotinic acetylcholine receptors (antagonist).
Primary metabolism is via CYP2D6 to noribogaine (12-hydroxyibogamine), which has an extended half-life of 28-49 hours and exhibits distinct pharmacology: biased kappa-opioid agonism (preferring G-protein over beta-arrestin), potent serotonin reuptake inhibition, and moderate mu-opioid receptor agonism. Noribogaine is considered the primary mediator of sustained anti-addictive and antidepressant effects.
The principal safety concern is cardiac: ibogaine blocks hERG potassium channels, producing dose-dependent QTc prolongation (mean 67.9ms in observational studies). This necessitates pre-treatment 12-lead ECG screening, comprehensive metabolic panel, and continuous cardiac telemetry during administration. Absolute contraindications include prolonged baseline QTc (>450ms women, >470ms men), structural heart disease, and concurrent QT-prolonging medications.
Receptor Pharmacology
Multi-Target Mechanism of Action
Mu-Opioid (MOR)
Partial agonist/antagonist activity produces rapid withdrawal interruption without precipitating severe withdrawal. Noribogaine provides sustained MOR modulation for 24-72+ hours post-treatment.
NMDA (GluN)
Non-competitive antagonism produces rapid antidepressant effects via enhanced synaptic plasticity and BDNF release. Similar mechanism to ketamine but with sustained action.
SERT (5-HTT)
Noribogaine is a potent serotonin reuptake inhibitor (Ki ~40 nM). Produces rapid serotonergic recalibration without the delayed onset characteristic of SSRIs.
DAT
Dopamine transporter modulation addresses anhedonia and reward system dysfunction. Combined with GDNF upregulation for dopamine neuron support.
Kappa-Opioid (KOR)
Noribogaine exhibits G-protein biased kappa agonism, producing anti-addictive effects without the dysphoria typically associated with kappa activation.
GDNF / BDNF
Upregulation of glial cell-derived and brain-derived neurotrophic factors creates an 8-12 week neuroplasticity window supporting sustained behavioral and neural changes.
Patient Selection
Inclusion and Exclusion Criteria
| Ibogaine | Exclusion | |
|---|---|---|
| Opioid Use Disorder | Primary indication — all opioid types including fentanyl | Active fentanyl use <48h (requires stabilization first) |
| Cardiac Status | Normal QTc, no structural disease, normal K+/Mg2+ | QTc >450ms (F) or >470ms (M), cardiomyopathy, arrhythmia |
| Psychiatric | Depression, PTSD, anxiety (comorbid or primary) | Active psychosis, bipolar I with recent mania, acute suicidality |
| Medications | Can taper SSRIs, SNRIs, benzos with medical supervision | Unable/unwilling to taper serotonergic or QT-prolonging meds |
| Hepatic Function | Normal or mildly elevated LFTs acceptable | Severe hepatic impairment (Child-Pugh C) |
| Substance History | Heroin, fentanyl, methadone, Suboxone, alcohol, stimulants | Active benzodiazepine dependency (requires separate taper protocol) |
| Age | 18-70 with appropriate medical clearance | <18 or >70 without case-by-case review |
| Motivation | Willing to engage in 90-day aftercare program | Seeking only acute withdrawal relief without ongoing support |
Referral Process
How to Refer a Patient to MindScape
1
Initial Contact
Contact our medical team directly for a physician-to-physician consultation. We discuss the patient case, review medical history, and assess candidacy. Email: medical@mindscaperetreat.com or call directly for immediate discussion.
2
Records Transfer
With patient consent, transfer relevant medical records: current medication list, recent cardiac workup (ECG, echocardiogram if available), metabolic panel, psychiatric history, and substance use timeline. We accept HIPAA-compliant secure transfer.
3
Pre-Treatment Coordination
Our team coordinates medication tapering with the referring physician. We provide specific tapering protocols for each medication class and maintain communication throughout. Joint management ensures patient safety during the transition.
4
Treatment & Monitoring
On-site medical supervision includes: pre-treatment ECG, comprehensive metabolic panel, continuous cardiac telemetry, hourly vital signs, and 72-hour post-treatment observation. Real-time updates provided to referring physician upon request.
5
Discharge & Continuity
Comprehensive discharge summary with clinical findings, treatment response, medication recommendations, and 90-day aftercare plan. We coordinate post-treatment care with referring physician for seamless continuity. Telehealth integration available.
Clinical Safety
Our Safety Protocol
MindScape operates under the clinical direction of Dr. Arellano, M.D., board-certified in addiction medicine with 900+ ibogaine treatments administered. Our facility maintains: 12-lead ECG capability with pre/post treatment comparison, continuous cardiac telemetry (Philips IntelliVue), crash cart with ACLS medications and defibrillator, arterial blood gas analysis, pulse oximetry and capnography, and 24/7 nursing coverage with 1:1 patient-to-nurse ratio during active treatment.
Our progressive dosing protocol (total alkaloid extract followed by ibogaine HCl) allows real-time dose titration based on patient response and cardiac parameters. This differs from the traditional single-dose flood approach and provides significantly enhanced safety margins. All vital signs are documented at 15-minute intervals during the acute phase and hourly during recovery.
We maintain a zero cardiac event record across 900+ treatments through rigorous pre-screening (sex-specific QTc thresholds, electrolyte optimization), progressive dosing, and continuous monitoring. We are transparent about ibogaine's cardiac risks and happy to discuss our safety data with any referring clinician.
Clinical Indications
Conditions We Treat
Opioid Use Disorder
Primary indication. Effective across all opioid types: heroin, fentanyl/analogues, prescription opioids, methadone, buprenorphine (Suboxone). Rapid withdrawal interruption with sustained anti-craving effects.
Treatment-Resistant Depression
Multi-receptor mechanism addresses TRD through simultaneous serotonin, dopamine, NMDA, and GDNF modulation. Sustained effects weeks to months post-treatment. Especially effective when comorbid with SUD.
PTSD / Complex Trauma
Stanford/VETS study (2024) documented 88% CAPS-5 score reduction in Special Operations veterans. Default mode network disruption enables deep trauma reprocessing during the ibogaine experience.
Other Substance Dependencies
Alcohol, cocaine, methamphetamine, kratom, and poly-substance dependency. Efficacy varies by substance — strongest evidence for opioids. Consultation recommended for non-opioid cases.
Published Evidence
Key References for Clinical Review
Mash DE et al. (2000) — Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. PMID: 11085338. Foundational pharmacokinetic characterization and safety data.
Baumann MH et al. (2001) — Noribogaine (12-hydroxyibogamine): a biologically active metabolite. PMID: 11458537. Established noribogaine as the primary sustained-action metabolite with distinct receptor pharmacology.
He DY & Ron D (2006) — Is GDNF a target for drugs of abuse? PMID: 16533525. Demonstrated ibogaine-mediated GDNF upregulation in dopaminergic regions.
Brown TK & Alper K (2018) — Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. PMID: 29526466. Systematic review showing 50-80% 12-month abstinence rates.
Davis AK et al. (2024) — Ibogaine treatment for veterans with TBI and PTSD. Nature Medicine. Prospective observational study documenting 88% PTSD symptom reduction in 30 SOF veterans.
Knuijver T et al. (2024) — Ibogaine treatment for substance use disorders: a systematic review. PMC11102648. Most recent comprehensive systematic review of ibogaine safety and efficacy data.
Clinician FAQ
Common Questions from Referring Physicians
Physician Consultation
Discuss a Patient Case With Our Clinical Team
Physician-to-Physician · Confidential · No Obligation
Schedule a Physician Consultation
100% Confidential · No Obligation
Latest Research & News
Feb 26, 2026
Texas Just Invested $50 Million in Ibogaine Research — Here's What That Means for the Future of Addiction Treatment
On February 20, 2026, the Texas state legislature approved the largest single investment in ibogaine research in America...
Read Article →Feb 26, 2026
Tennessee Proposes $5 Million for Ibogaine Research — Veterans Say "No One Should Have to Leave the Country We Serve"
Tom Aceto stood in front of Tennessee lawmakers this week and said something that should make every American uncomfortab...
Read Article →Feb 25, 2026
How to Evaluate Ibogaine Clinics: A Medical Safety Checklist
Choosing an ibogaine treatment facility is one of the most important decisions you'll make in your recovery journey. Unl...
Read Article →